FasterCures

FasterCures is a non-profit organization that aims to accelerate the pace of biomedical research and medical innovation. It was established in 2003 and is based in Washington, D.C., United States. The organization works to improve the medical research system so that it can quickly respond to the needs of patients and deliver new therapies more efficiently.

History

FasterCures was founded in 2003 by Michael Milken, a financier and philanthropist. The organization was established with the goal of speeding up the process of turning lab discoveries into new therapies for patients. Since its inception, FasterCures has been working to identify and implement ways to reduce the time it takes to develop new treatments and cures.

Mission and Work

The mission of FasterCures is to save lives by speeding up and improving the medical research system. The organization works towards this mission by focusing on a few key areas:

• Collaboration: FasterCures promotes collaboration among all stakeholders in the medical research system, including researchers, patients, government agencies, and industry. It believes that by working together, these groups can accelerate the pace of medical innovation.

• Patient Engagement: FasterCures advocates for the active involvement of patients in the research process. It believes that patients can provide valuable insights and perspectives that can help guide research and development efforts.

• Regulatory Innovation: FasterCures works to modernize the regulatory system for medical products. It believes that a more efficient and effective regulatory system can help bring new treatments to patients more quickly.

Impact

FasterCures has had a significant impact on the medical research system. It has helped to foster a culture of collaboration and patient engagement in research, and it has advocated for regulatory reforms that have helped to speed up the development of new treatments. The organization's work has been recognized by a number of organizations and publications, including Forbes, The Wall Street Journal, and The New York Times.

See Also

• Medical research
• Patient advocacy
• Regulatory affairs